<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012319</url>
  </required_header>
  <id_info>
    <org_study_id>COVIDTX-CTP-07</org_study_id>
    <nct_id>NCT05012319</nct_id>
  </id_info>
  <brief_title>Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19</brief_title>
  <official_title>A Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salmaniya Medical Complex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salmaniya Medical Complex</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy study&#xD;
      evaluating NONS in adult volunteers as a treatment for high-risk asymptomatic and symptomatic&#xD;
      individuals with mild COVID-19 infection. thru facility).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy study&#xD;
      evaluating NONS in adult volunteers as a treatment for high-risk asymptomatic and symptomatic&#xD;
      individuals with mild COVID-19 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in healthy adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>the list of the members of the resrach team who will be blinided have been identiifed and a full procedure has been identified</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of NONS compared to placebo in participants with COVID-19 to reduce the need of urgent care</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of NONS compared to placebo to reduce the need for urgent medical care in term of the need of visiting the emergency room in participants with COVID-19 infection and reduce of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of NONS compared to placebo in participants with COVID-19 to reduce mortality</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of NONS compared to placebo to reduce mortality of participants with COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of NONS compared to placebo in participants with COVID-19 on viral load reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Viral load reduction measure in copies per ml in participants with mild COVID-19 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of NONS compared to placebo in participants with COVID-19 to reduce time of clinical symptoms improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Median time reduction to COVID-19 clinical symptoms improvement in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events to assess Safety and Tolerability]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitric Oxide Nasal Spray &quot;Enovid&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>to be given as a treatment</intervention_name>
    <description>Nitric Oxide Nasal Spray &quot;Enovid&quot;</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria:&#xD;
&#xD;
          -  18 years and above.&#xD;
&#xD;
          -  COVID-19 infection Confirmed with a laboratory SARS-CoV-2 RT-PCR nasal swab or antigen&#xD;
             test. COVID-19 test specimen must be collected 48 hours prior to Screenings.&#xD;
&#xD;
          -  Mild COVID-19 Infection defined as:&#xD;
&#xD;
               -  No Pneumonia (negative by chest auscultation or Chest X Ray).&#xD;
&#xD;
               -  No Shortness of breath.&#xD;
&#xD;
               -  No Tachypnea (respiratory rate &lt;20 breathes/min)&#xD;
&#xD;
               -  No Hypoxia (Oxygen saturation &gt;93% on RA)&#xD;
&#xD;
               -  Fever &lt;38 degrees.&#xD;
&#xD;
               -  No Chest Pain.&#xD;
&#xD;
               -  No Mental Status Change.&#xD;
&#xD;
          -  Asymptomatic participants must be high risk defined as (any of the following):&#xD;
&#xD;
               -  Smokers (at least 5 cigarettes per day)&#xD;
&#xD;
               -  BMI (&gt; 40 kg/m2)&#xD;
&#xD;
               -  History of cardiac or chronic lung disease&#xD;
&#xD;
               -  Clotting predisposing conditions (hemophilia, von Willebrand's disease)&#xD;
&#xD;
               -  Sickle cell disease&#xD;
&#xD;
               -  Immunocompromised such as HIV , cancer , on immunosuppressant medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants diagnosed with another (non-COVID-19) respiratory infection.&#xD;
&#xD;
          -  Participants with a current tracheostomy or laryngectomy.&#xD;
&#xD;
          -  Participants who are receiving concomitant respiratory therapy such as oxygen,&#xD;
             positive airway pressure or ventilatory support. NOTE: Positive airway pressure for&#xD;
             obstructive sleep apnea is permitted if the treatment was established with good&#xD;
             compliance for at least 3 months before study enrollment.&#xD;
&#xD;
          -  Participants with newly diagnosed illnesses that are not deemed stable by the&#xD;
             participant's primary care physician), based on Investigator assessment of medical&#xD;
             history during Screening.&#xD;
&#xD;
          -  Participants who use intranasally dosed drugs, prescriptions or over-the-counter&#xD;
             medications such as fluticasone.&#xD;
&#xD;
          -  Participants who need hospitalization for reasons other than COVID-19 infection.&#xD;
&#xD;
          -  Participants who are unable to safely self-administer the nasal spray as directed.&#xD;
&#xD;
          -  Clinical signs indicative of moderate, severe, or critical COVID severity symptoms&#xD;
             (requirement for supplemental oxygen, limitation of activities due to COVID-19&#xD;
             symptoms).&#xD;
&#xD;
          -  Females who are breastfeeding, pregnant, or attempting to become pregnant.&#xD;
&#xD;
          -  Participants who have experienced symptoms of COVID-19 for more than 7 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Participants who have any other condition that, in the opinion of the Investigator,&#xD;
             would interfere with a participant's ability to adhere to the protocol (eg,&#xD;
             participants who are mentally or neurologically disabled and who are considered not&#xD;
             fit for their participation in the study), interfere with assessment of the&#xD;
             investigational product, or compromise the safety of the participant, or the quality&#xD;
             of the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jameela m alsalman, MD</last_name>
    <phone>0097336515138</phone>
    <email>jsalman@health.gov.bh</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariam alalawi, md</last_name>
    <phone>0097339960004</phone>
    <email>malalawi31@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abdulla Kanoo Center,</name>
      <address>
        <city>A'ali</city>
        <state>Building 556</state>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>reem j ahmed</last_name>
      <phone>0097333731313</phone>
      <email>RAhmed4@health.gov.bh)</email>
    </contact>
    <contact_backup>
      <last_name>fatima alnashaba, md</last_name>
      <phone>0097333779876</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bahrain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Salmaniya Medical Complex</investigator_affiliation>
    <investigator_full_name>jameela al salman</investigator_full_name>
    <investigator_title>infectious disease consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

